Ana Pocivavsek to Schizophrenia
This is a "connection" page, showing publications Ana Pocivavsek has written about Schizophrenia.
Connection Strength
1.640
-
Basic Neuroscience Illuminates Causal Relationship Between Sleep and Memory: Translating to Schizophrenia. Schizophr Bull. 2018 01 13; 44(1):7-14.
Score: 0.529
-
Exposure to elevated embryonic kynurenine in rats: Sex-dependent learning and memory impairments in adult offspring. Neurobiol Learn Mem. 2020 10; 174:107282.
Score: 0.158
-
The Effects of a Gluten-Free Diet on Immune Markers and Kynurenic Acid Pathway Metabolites in Patients With Schizophrenia Positive for Antigliadin Antibodies Immunoglobulin G. J Clin Psychopharmacol. 2020 May/Jun; 40(3):317-319.
Score: 0.155
-
Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia. Neuropsychopharmacology. 2018 07; 43(8):1706-1711.
Score: 0.135
-
Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia. Neuropsychopharmacology. 2018 07; 43(8):1675-1680.
Score: 0.133
-
Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood. Psychopharmacology (Berl). 2018 03; 235(3):651-661.
Score: 0.131
-
Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders. Biol Psychiatry. 2017 Nov 15; 82(10):756-765.
Score: 0.123
-
Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding. Psychopharmacology (Berl). 2016 Oct; 233(21-22):3725-3735.
Score: 0.120
-
Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. JAMA Psychiatry. 2014 Jul 01; 71(7):761-8.
Score: 0.104
-
Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia. Neuropharmacology. 2015 Mar; 90:33-41.
Score: 0.027
-
Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor. Schizophr Bull. 2014 Mar; 40 Suppl 2:S152-8.
Score: 0.025